Introduction {#s1}
============

Excitatory synapses are the contact sites through which neurons communicate with each other. These synapses are asymmetric structures that are formed by pre- and postsynaptic terminals containing distinct sets of proteins. Incoming action potentials are converted into chemical signals (neurotransmitters) at presynaptic terminals, which subsequently pass through the synaptic cleft and are reconverted into electrical signals at postsynaptic sites ([@bib24]). These synaptic contacts are not static but are able to undergo structural changes and thereby modify neuronal network computation ([@bib30]). At postsynaptic sites, interacting proteins are densely packed into a sub-membrane structure called the postsynaptic density (PSD) ([@bib40]). Scaffold proteins of the PSD-95 family membrane-associated guanylate kinases (MAGUKs) are highly abundant components of the PSD and function as central regulators of postsynaptic organisation ([@bib55]). PSD-95 family MAGUKs contain three PDZ domains that are known to directly interact with N-methyl-D-aspartate (NMDA) receptor C-termini ([@bib17]), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor C-termini ([@bib22]), and AMPA receptor auxiliary subunit C-termini ([@bib6]). The PDZ domains are followed by an SH3 - guanylate kinase (GK) domain tandem ([@bib13]). The MAGUK SH3 domain lost its function to bind proline-rich peptides; instead it forms an intramolecular interaction with the GK domain ([@bib27]). Similarly, the PSD-95 GK domain is atypical in that it is unable to phosphorylate GMP but has evolved as a protein interaction domain ([@bib15]). Binding of known interactors to the GK domain typically involves residues of the canonical GMP-binding region ([@bib36]; [@bib54]; [@bib56]). This modular array of protein interaction domains allows PSD-95 MAGUKs to function as bidirectional organisers of synaptic function. First, neurotransmitter receptors can be incorporated or removed from postsynaptic membranes, depending on molecular interactions with these sub-membrane scaffold proteins. Second, together with other scaffold proteins at postsynaptic sites, they align downstream effectors and cytoskeletal proteins. Accordingly, PSD-95 family MAGUKs are essential for the establishment of long-term potentiation (LTP) by regulating the content of AMPA receptors at dendritic spines ([@bib8]; [@bib32]; [@bib39]). In line with this is the observation that acute knockdown of PSD-95 MAGUKs leads to a decrease in postsynaptic AMPA and NMDA receptor-mediated synaptic transmission as well as a reduction in PSD size ([@bib5]). Taken together, exploring protein complex formation directed by PSD-95 MAGUK family members is of central importance for understanding regulation of synaptic transmission. We have previously shown that the synaptic MAGUK protein PSD-95 oligomerises upon binding of monomeric CRIPT-derived PDZ~3~ ligands (ligands that specifically bind to the third PDZ domain) ([@bib34]) and speculated that ligand - PDZ~3~ domain binding induces conformational changes in the C-terminal domains that lead to complex formation. Our initial observations of PDZ ligand-induced effects in PSD-95 MAGUK proteins have recently been supported by other studies ([@bib51]; [@bib52]).

In this study, we use a bimolecular fluorescence complementation (BiFC) assay to show that PSD-95 oligomerisation can be triggered by Neuroligin-1 (NLGN1) and that this is dependent on the C-terminal SH3-GK domain tandem. Moreover, we identify new interaction partners of PSD-95 C-terminal domains by quantitative mass spectrometry. We provide evidence that the heterotrimeric G protein subunit Gnb5 is a novel GK domain interactor and that its ability to bind to PSD-95 is likewise promoted by binding of a ligand to the PSD-95 PDZ~3~ domain.

Results {#s2}
=======

Neuroligin-1 binding to PSD-95 PDZ~3~ domains facilitates oligomerisation guided by the PSG module {#s2-1}
--------------------------------------------------------------------------------------------------

We are interested in the functional coupling of PDZ~3~ domains with the adjacent SH3-GK domain tandem in the synaptic scaffold protein PSD-95 (termed PSG module, see [Figure 1A](#fig1){ref-type="fig"} for domain structure) and the relevance of ligand - PDZ~3~ domain interactions for PSD-95 complex formation. To explore this idea, we built on our previous work with tagged cytosolic CRIPT-derived PDZ~3~ ligands ([@bib34]) and we have now designed a cell-based assay to directly monitor the proximity of PSD-95 molecules by bimolecular fluorescence complementation (BiFC). Expression constructs of PSD-95 were fused to non-fluorescent halves of EYFP (N-terminal half = YN and C-terminal half = YC) and coexpressed with the established PDZ domain ligand Neuroligin-1 (NLGN1) in HEK-293T cells. NLGN1 is a synaptic adhesion molecule that specifically binds to the third PDZ domain of PSD-95 ([@bib14]). Coexpression of the *per se* non-fluorescent PSD-95-YN and PSD-95-YC constructs (together referred to as WT/WTsplitEYFP) with full-length NLGN1 led to the formation of multimolecular fluorescent PSD-95 complexes that were located at the cell membrane, recapitulating the natural localisation of the endogenous protein complexes ([Figure 1B](#fig1){ref-type="fig"}), and highlighting that the PSD-95 C-termini (which harbour the splitEYFP tags) are in close proximity to each other in these complexes.

![PDZ~3~ ligand-induced dynamics in the PDZ~3~-SH3-GK module facilitate oligomerisation.\
(**A**) Schematic representation of the PSD-95 domain organisation. PSD-95 contains three PDZ domains followed by a SH3-GK domain tandem. The PSG module (**P**DZ~3~-**S**H3-**G**K) is common to the MAGUK protein family. (**B**) Live-cell microscopy of HEK-293T cells transfected with PSD-95-YN, PSD-95-YC and full-length Neuroligin-1 reveals a membrane associated localisation of the refolded complex (transfection corresponding to WT/WTsplitEYFP plus NLGN1 in [Figure 1C,D](#fig1){ref-type="fig"}). Scale bar: 10 µm. (**C**, **D**) PSD-95 oligomerisation assay based on BiFC. HEK-293T cells were triple-transfected with the displayed DNA constructs and EYFP refolding was assessed by flow cytometry. Formation of oligomeric fluorescent complexes is effective in the presence of wild-type Neuroligin-1 (NLGN1). (**C**) Fluorescence is almost not detectable by coexpression of SynCAM1 (SynCAM1 is not binding to PSD-95 PDZ domains) (**D**) Fluorescence is reduced by either site-directed mutagenesis of the NLGN1 PDZ~3~ ligand C- terminus (mutNLGN1: TTRV ► T**A**R**A**), or a targeted amino acid exchange in the PSD-95 SH3 domain (L460P). (**C**, **D**) The dot plots indicate mean values (black horizontal bar) with SD (red vertical bar), based on twelve individual measurements (dots) that originate from four independent experiments (results from each experiment are triplicates for each DNA construct combination). Data were analysed by one-way ANOVA/Sidak\'s multiple comparisons test. \*\*\*\*p\<0.0001. (**E**) MYC-PSG and FLAG-SH3-GK or FLAG-GK were coexpressed together with either CRIPT-derived PDZ~3~ or mutPDZ~3~ ligand constructs. Upon MYC-PSG IP, proteins were analysed by western blot with αFLAG antibodies. Coexpression of the CRIPT-derived PDZ~3~ ligand enhanced the coIP of PSG and GK, whereas coIP of PSG and SH3-GK was negligible regardless of whether or not the CRIPT-derived PDZ~3~ ligand construct was coexpressed. The western blot shown (left side) is a representative example of three independent experiments; the corresponding quantification of coIP band intensities from these three experiments is shown in the dot plot on the right side indicating mean values ± SEM.\
10.7554/eLife.41299.003Figure 1---source data 1.Source data for [Figure 1C,D](#fig1){ref-type="fig"}.\
10.7554/eLife.41299.004Figure 1---source data 2.Source data for [Figure 1E](#fig1){ref-type="fig"}.](elife-41299-fig1){#fig1}

In order to quantify the formation of these fluorescent protein complexes, we used flow cytometry. In initial experiments ([Figure 1C](#fig1){ref-type="fig"}, see also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for gating strategy), we validated that efficient refolding of splitEYFP halves fused to wild-type PSD-95 indeed relied on the presence of a PDZ-binding ligand that interacts with PSD-95. For comparison, we took advantage of the synaptic cell adhesion molecule SynCAM1. SynCAMs, like NLGNs, are trans-synaptic membrane proteins; however, they differ from NLGN family members at the C-terminus and bind exclusively to class II PDZ domains (*e.g.* CASK, MPP2) rather than class I PDZ domains (such as PSD-95 PDZ domains) ([@bib3]). When we express the splitEYFP-tagged wild-type PSD-95 molecules together with SynCAM1, we do not induce refolding of splitEYFP ([Figure 1C](#fig1){ref-type="fig"}), suggesting that it is indeed the PDZ domain interactions between the transmembrane protein and wild-type PSD-95 that facilitate the observed formation of multimolecular PSD-95 complexes in which the splitEYFP halves refold efficiently.

We validated this idea in a second set of experiments by taking advantage of a targeted mutation of the PDZ-binding sequence of NLGN1: we generated mutant NLGN1 variants that carry two alanine substitutions within the C-terminal PDZ~3 ~ligand sequence (mutNLGN1: C-terminus TTRV ► T**A**R**A**). Upon coexpression of this mutNLGN1 with splitEYFP-tagged PSD-95 molecules, the detected fluorescence intensity decreased by approximately 40% relative to that after coexpression with wild-type NLGN1 ([Figure 1D](#fig1){ref-type="fig"}, see also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for gating strategy), supporting the idea that indeed the ligand - PDZ domain interaction is critical for PSD-95 complex formation in our assay. Finally, we investigated the hypothesis that the natural PSD-95 SH3-GK conformation is also important in this PDZ ligand-mediated scaffolding process. Leucine 460 is an internal SH3 domain residue and the L460P mutation has been shown to specifically disrupt the intramolecular SH3-GK domain interaction ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) ([@bib28]; [@bib41]) that is one of the hallmark features of MAGUK proteins ([@bib44]). Interestingly, this amino acid exchange does not interfere with PDZ~3~ ligand binding ([@bib34]) but strongly abolishes PSD-95 complex assembly, as observed by EYFP refolding ([Figure 1D](#fig1){ref-type="fig"}). We assume that in the context of the full-length protein, the L460P mutation likewise weakens the (intramolecular) interaction between the SH3 and GK domains, which would then result in a constitutively 'open' conformation. The profound negative effect that we observe following a targeted amino acid exchange in the SH3 domain highlights the importance of the SH3-GK domain tandem for its involvement in regulated PSD-95 oligomerisation.

Binding of a CRIPT-derived PDZ ligand to PSD-95 PDZ~3~ facilitates an 'open' SH3-GK state that frees both domains for binding in *trans* {#s2-2}
----------------------------------------------------------------------------------------------------------------------------------------

In line with our BiFC assay results, we have previously reported that PSD-95 constructs (full-length and the isolated PSG module) efficiently oligomerise and coprecipitate upon binding of a PDZ~3~ ligand ([@bib34]). Moreover, the observation by NMR spectroscopy that the PSG module forms a dynamic modular entity ([@bib53]) led us to hypothesise that this type of ligand binding to PDZ~3~ might influence intramolecular SH3-GK domain assembly, facilitating the formation of domain swapped oligomers ([@bib27]; [@bib49]). For these experiments, we again took advantage of the PSD-95 interactor CRIPT, which is a cytosolic protein that has been shown to interact predominantly with the third PDZ domain of PSD-95 ([@bib29]). Specifically, we asked whether the ligand - PDZ~3~ domain interaction might release the intramolecular SH3-GK domain assembly, thereby allowing other domains and proteins to interact in *trans*. To explore this idea, we assessed which PSD-95 domains are able to interact in *trans* upon binding of a CRIPT-derived PDZ~3~ ligand to proteins that harbour the PSG module, using a coimmunoprecipitation experiment designed accordingly.

Our strategy involves expression of the PSD-95 PSG module together with mCherry-tagged PDZ~3~ ligands, consisting of the last 10 amino acids of CRIPT (DTKNYKQTSV) ([@bib29]). As a control, comparable constructs carrying two amino acid exchanges within the PDZ~3~ ligand sequence (DTKNYKQ**A**S**A**) were used. In our hands, this mutation in the CRIPT C-terminus almost completely abrogates binding to PDZ~3~, as observed by coIP ([@bib34]), making it an ideal control for our coIP approach that targets the ligand - PDZ~3~ interaction. Upon triple transfection with either a GK or an SH3-GK domain construct and the CRIPT-derived PDZ~3~ ligand, the PSG modules were precipitated, and copurified proteins were analysed by western blot ([Figure 1E](#fig1){ref-type="fig"}). The SH3-GK construct did not coprecipitate with the PSG module regardless of whether it was coexpressed with wild-type or mutant CRIPT-derived PDZ~3~ ligands. This may be due to a constitutive intramolecular association of the SH3 and GK domains, leading to a 'closed' SH3-GK assembly, with no ability to bind a PSG module in *trans*. The GK domain alone, however, coprecipitated effectively with the PSG module, when expressed in the presence of functional CRIPT-derived PDZ~3~ ligands. These data suggest that binding of a CRIPT-derived PDZ~3~ ligand renders the PSG module 'interaction-competent'; that is it facilitates formation of a conformational state in which it is able to bind isolated GK domain constructs in *trans*. In this experiment, the intramolecular SH3-GK domain assembly resembles the 'interaction-incompetent' state, and the SH3 domain autoinhibits the GK domain's interaction activity.

The SH3-GK assembly state influences PSD-95 interactions {#s2-3}
--------------------------------------------------------

Based on the above results, we propose that PSD-95 C-termini can adopt different functional states depending on whether or not CRIPT-derived PDZ~3~ ligands are bound to PSD-95 PDZ~3~ domains, *i.e.* ligand binding induces a loosening of the intramolecular SH3-GK domain assembly and renders the SH3-GK domain tandem 'interaction-competent'. In order to identify interactors that differentially bind to PSD-95 C-termini in an 'open state' versus PSD-95 molecules where the GK domain is autoinhibited by an intramolecular interaction with the adjacent SH3 domain, we utilised a quantitative proteomics strategy. In a reductionist approach, we mimic the open and closed states with different bacterially expressed GST fusion proteins: a GST-GK construct serves as the 'interaction-competent' GK domain state, whereas a GST-SH3-GK domain fusion protein reflects the autoinhibited domain assembly. By performing GST pull-downs from crude synaptosome preparations followed by quantitative mass spectrometric analysis we aimed to identify novel proteins that preferentially bind to the 'open' or 'closed' state of the PSD-95 C-terminal domains ([Figure 2A](#fig2){ref-type="fig"}).

![Identification of interactors that differentially bind to PSD-95 C-terminal domains.\
(**A**) Schematic representation of the quantitative mass spectrometry experiment to identify PSD-95 GK domain interactors from crude rat synaptosomes by GST pull-down of bacterially expressed GST-GK or GST-SH3-GK constructs and ^18^O-labeling. (**B**) GST pull-downs were performed in triplicates and 278 interacting proteins that passed our threshold settings were identified and quantified by mass spectrometry. Proteins are ranked by their mean L/H ratio indicating preferential enrichment with either GST-GK or GST-SH3-GK constructs. The heterotrimeric G protein subunit Gnb5 was found to be enriched in the GST-GK fraction relative to the GST-SH3-GK fraction and selected for further studies.\
10.7554/eLife.41299.008Figure 2---source data 1.Source data for [Figure 2B](#fig2){ref-type="fig"}.](elife-41299-fig2){#fig2}

Bacterially expressed GST-GK vs. GST-SH3-GK constructs were incubated with solubilised proteins from crude synaptosome preparations of whole rat brains in triplicates. Interacting proteins were eluted from the beads and separated by SDS-PAGE. Enzymatic ^16^O/^18^O-labelling during tryptic in-gel digestion was used for relative quantification of proteins by nanoLC-MS/MS analysis. Proteins enriched by GST-GK were labelled light (^16^O), while proteins enriched by GST-SH3-GK were labelled heavy (^18^O). In total, we reproducibly identified and quantified 278 proteins ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Remarkably, 230 (≈ 82%) of these have been reported to be present in mouse and/or human cortical postsynaptic density fractions ([@bib2]). Moreover, we also identified the known GK-domain interacting proteins Map1A ([@bib36]), Mark2 ([@bib47]), Dlgap2 ([@bib43]) and Srcin1/p140CAP ([@bib11]), validating the general success of our approach. Potential binders to the GST-GK construct are expected to be enriched in their light form (L/H ratio \>1), while binders to the GST-SH3-GK construct are expected to be enriched in their heavy form (L/H ratio \<1). Unexpectedly, we isolated several heterotrimeric G protein subunits enriched in the protein fractions that bind preferentially to the GST-GK construct ([Figure 2B](#fig2){ref-type="fig"}). Of special interest was the guanine nucleotide binding protein beta 5 (Gnb5), which is a signalling effector downstream of GPCRs that exhibits inhibitory activity in neurons ([@bib48]; [@bib33]). Gnb5 contains an N-terminal α-helix followed by a β-sheet propeller composed of seven WD-40 repeats ([@bib4]). Gnb5 is specifically expressed in brain ([@bib46]) and mutations in the Gnb5 gene cause a multisystem syndrome with intellectual disability in patients ([@bib25]).

Gnb5 is a novel synaptic PSD-95 complex partner {#s2-4}
-----------------------------------------------

In order to verify Gnb5 as a potential binding partner from the above mass spectrometry result, we performed a GST pull-down from crude rat brain synaptosomes and analysed the associated proteins by western blot ([Figure 3A](#fig3){ref-type="fig"}). We could not detect Gnb5 in the bead control pull-down lane and almost no Gnb5 was detectable in the GST-SH3-GK lane. However, a clear Gnb5 signal was present in the GST-GK lane, supporting our quantitative mass spectrometry results and suggesting that a Gnb5 - GK domain interaction is favoured over a Gnb5 - SH3-GK domain interaction. Additionally, we observed a preferred interaction of overexpressed Gnb5 with the isolated GK domain compared to SH3-GK domain constructs in COS-7 cells. Upon IP of Gnb5 tagged with the green fluorescent protein Clover ([@bib19]) using αGFP antibodies, the isolated GK domain coprecipitates far more efficiently than does the SH3-GK domain ([Figure 3B](#fig3){ref-type="fig"}).

![The heterotrimeric G protein subunit Gnb5 is a novel PSD-95 interactor.\
(**A**) GST pull-down from crude synaptosomal proteins (comparable amounts of GST tagged proteins observable by Coomassie, upper panel) enabled comparison of Gnb5 binding to the GK domain alone versus the SH3-GK domain. Gnb5 is effectively enriched in the GST-GK pull-down compared to bead controls or GST-SH3-GK pull-downs, as observed by western blot with a commercially available αGnb5 antibody (lower panel). The GST pull-down shown on the left side is a representative example of three independent experiments; the corresponding quantification of copurified Gnb5 band intensities from these three experiments is shown in the dot plot on the right side indicating mean values ± SEM. (**B**) CoIP experiment of tagged Gnb5 (Gnb5-Clover) with tagged SH3-GK or GK (FLAG-SH3-GK or FLAG-GK). Immunoprecipitation of Gnb5-Clover with αGFP antibody efficiently copurified the GK-domain construct (observed via western blot with αFLAG antibodies, lower panel). The western blot shown (left side) is a representative example of three independent experiments; the corresponding quantification of coIP band intensities from these three experiments is shown in the dot plot on the right side indicating mean values ± SEM. (**C**) Cultures of rat hippocampal neurons (E18) were fixed at DIV21 and stained for Gnb5 together with the dendritic marker MAP2 (microtubule-associated protein 2) and either the postsynaptic protein PSD-95 (left panel) or the presynaptic marker Synapsin (right panel) and respective fluorescent secondary antibodies, and visualised by confocal microscopy. Scale bars: 5 μm.\
10.7554/eLife.41299.010Figure 3---source data 1.Source data for [Figure 3A,B](#fig3){ref-type="fig"}.](elife-41299-fig3){#fig3}

Our *in vitro* experiments clearly indicate that Gnb5 is an interactor of PSD-95 C-terminal domains. However, our interaction data do not clearly indicate in which subcellular compartment Gnb5 and the Gnb5 - PSD-95 complex is located. To explore this, we immunostained cultures of dissociated cells from rat hippocampi and analysed the subcellular distribution of endogenous proteins. We stained fixed cultures (DIV21) with antibodies against Gnb5 and costained for the dendritic marker MAP2 and for PSD-95. Gnb5 staining was present in neuronal dendrites, where the signal overlaps with the PSD-95 staining ([Figure 3C](#fig3){ref-type="fig"}). Additionally, we stained neurons with antibodies against Gnb5, MAP2 and the presynaptic marker Synapsin. In these experiments, the Gnb5 signal is adjacent to the presynaptic Synapsin signal ([Figure 3C](#fig3){ref-type="fig"}). Together, these findings strongly support the idea that Gnb5 and PSD-95 are protein complex partners at postsynaptic sites of hippocampal neurons.

Regulation of PSD-95 complex formation {#s2-5}
--------------------------------------

Our data indicate that Gnb5 interacts differentially with PSD-95 C-terminal constructs and we observe that PSD-95 and Gnb5 exhibit overlapping expression at postsynaptic sites. We next set out to determine if the PSD-95 - Gnb5 interaction is indeed influenced by the presence of synaptic PDZ~3~ ligands, as we initially hypothesised. We coexpressed PSD-95 with CRIPT-derived PDZ~3~ ligand constructs as in previous experiments, together with Gnb5. Following IP of PSD-95, the precipitates were analysed by western blot: the presence of these PDZ~3~ ligands indeed triggered coimmunoprecipitation of Gnb5 and PSD-95, which supports the idea that ligand binding to PDZ~3~ indirectly affects protein-protein interactions at neighbouring domains. Gnb5 lacking the N-terminal α-helix (shortGnb5) coprecipitated somewhat less efficiently than the full-length protein ([Figure 4A](#fig4){ref-type="fig"}), suggesting that this N-terminal region of Gnb5 (amino acids 1--33) is important for the PDZ~3~ ligand-mediated interaction with PSD-95.

![Gnb5 - PSD-95 complex formation is regulated by CRIPT-derived PDZ~3~ ligand binding.\
For this figure, western blots shown on the left side are representative examples of three independent experiments; the corresponding quantification of coIP band intensities from these three experiments are shown in the dot plots on the right side indicating mean values ± SEM. (**A**) MYC-PSD-95 and FLAG-Gnb5 or FLAG-shortGnb5 were coexpressed with either CRIPT-derived PDZ~3~ or mutPDZ~3~ ligand constructs. MYC-PSD-95 was precipitated and proteins were analysed by western blot with αFLAG antibodies. Coexpression of the CRIPT-derived PDZ~3~ ligand facilitated the coIP of PSD-95 and Gnb5, coIP with the shortGnb5 construct (N-terminal truncation) was much less efficient. In the presence of the CRIPT-derived mutPDZ~3~ ligand, coprecipitated proteins were not detectable. (**B**) CoIP of MYC-PSG and FLAG-Gnb5 together with either CRIPT-derived PDZ~3~ or mutPDZ~3~ ligand constructs. The presence of CRIPT-derived PDZ~3~ ligand constructs facilitated coprecipitation of PSG and Gnb5 (see comparative western blot with αFLAG antibodies, lower panel). (**C**) Coexpression of MYC-PSG or MYC-PSG L460P with FLAG-Gnb5 and subsequent MYC IP. PSG L460P IP efficiently copurifies Gnb5 (observed by western blot with αFLAG antibodies).\
10.7554/eLife.41299.012Figure 4---source data 1.Source data for [Figure 4](#fig4){ref-type="fig"}.](elife-41299-fig4){#fig4}

Next, we asked if the PSD-95 PSG module is sufficient to bind to Gnb5 in a ligand-triggered mode. We coexpressed a PSG expression construct together with Gnb5 and CRIPT-derived PDZ~3~ ligand constructs (wild-type or mutant) and performed pull-downs of the PSG constructs or unspecific IgGs as a control. Upon analysis of the precipitates by western blot, we detected a robust coIP of Gnb5 with the PSG module construct in the presence of this type of PDZ~3~ ligand ([Figure 4B](#fig4){ref-type="fig"}). Clearly, the PSG module is sufficient for ligand-triggered coimmunoprecipitation of Gnb5.

Our comparative mass spectrometry results for Gnb5, together with subsequent PSD-95 coimmunoprecipitation data, support the idea that ligand binding can influence the PSD-95 PSG module such that its protein interaction profile resembles that of the isolated GK domain, that is it differs from the SH3-GK domain tandem with regard to protein--protein interactions (see [Figure 1E](#fig1){ref-type="fig"}). In summary, we propose that binding of a PDZ~3~ ligand weakens the intramolecular SH3-GK domain association, which then enables the individual SH3 and GK domains to participate in *trans* interactions with other molecules. To test this model, we took advantage of the PSD-95 L460P mutation, which is known to disrupt the well-characterised intramolecular SH3-GK domain assembly, thus aberrantly releasing the GK domain from its SH3 domain-mediated inhibition. Upon coexpression of wild-type or mutant (L460P) PSG proteins together with Gnb5, we performed pull-downs of the PSG proteins and comparatively assessed coprecipitation of Gnb5. Gnb5 did not coprecipitate efficiently with the wild-type PSG module but was effectively coprecipitated by the PSG module harbouring the L460P mutation that disrupts the intramolecular SH3-GK domain interaction ([Figure 4C](#fig4){ref-type="fig"}). We conclude that Gnb5 is interacting with the PSD-95 PSG module in one of two possible modes. Gnb5 could bind at GK domain sites that are directly occupied by the neighbouring SH3 domain (and thereby compete with the SH3 domain for interaction with the GK domain). Alternatively, Gnb5 could bind to GK domain sites on distant surfaces (e.g. the canonical GMP-binding region) that are not directly influenced by intramolecular SH3-GK interactions but might be allosterically regulated by changes to the PSG module.

GK domain interactions are differentially regulated {#s2-6}
---------------------------------------------------

In order to explore these two possibilities in more depth, we took advantage of established knowledge on the structure of GK domains and information on previously identified GK-interacting proteins. The GK domain of PSD-95 has evolved from an enzyme that catalyses the phosphorylation of GMP to an enzymatically inactive protein interaction domain. Interestingly, various PSD-95 GK-interacting proteins bind to the canonical GMP-binding region, and by exchanging arginine 568 (which is situated in the ancestral GMP-binding site) to alanine (R568A), these interactions can be specifically disrupted ([@bib36]). In order to gain insight into the nature of the binding of Gnb5 to the PSD-95 GK domain, we compared PSD-95 - Gnb5 binding to PSD-95 - GKAP binding. GKAP ('GK'-associated protein, also referred to as SAPAP1 or DLGAP1) is an established synaptic GK domain binder ([@bib16]) whose interaction involves the GMP-binding region ([@bib57]). These ideas are also validated by our own coimmunoprecipitation experiments: GKAP can be efficiently coprecipitated upon pull-down of either the isolated GK domain or an intact PSG module, whereas a recombinant PSG module harbouring the GMP binding site mutation R568A fails to precipitate GKAP ([Figure 5A](#fig5){ref-type="fig"}). In experiments with PSD-95 and Gnb5, however, the same mutation had no effect on coprecipitation of Gnb5 ([Figure 5B](#fig5){ref-type="fig"}), suggesting that GKAP and Gnb5 proteins bind to PSD-95 GK domains in fundamentally different ways.

![GK domain interactions are differentially regulated.\
For this figure, western blots shown on the left side are representative examples of three independent experiments; the corresponding quantification of coIP band intensities from these three experiments are shown in the dot plots on the right side indicating mean values ± SEM. (**A**) MYC-PSG, MYC-PSG R568A and MYC-GK were coexpressed with FLAG-GKAP. Following MYC IP, precipitated proteins were analysed by western blot. GKAP coprecipitated with PSG and GK domain constructs. The GK domain mutant PSG R568A was not able to bind GKAP. (**B**) Following coexpression of MYC-PSD-95 or MYC-PSD-95 R568A with FLAG-Gnb5, together with either CRIPT-derived PDZ~3~ or mutPDZ~3~ ligand, proteins were precipitated with αMYC-antibody and analysed by western blot. Gnb5 coIP with either PSD-95 or PSD-95 R568A was efficiently promoted by the presence of PDZ~3~-binding ligand, irrespective of the GK domain mutation R568A. (**C**) CoIP of MYC-PSD-95 and FLAG-GKAP together with either CRIPT-derived PDZ~3~ or mutPDZ~3~ ligand constructs and analysis of precipitated proteins by western blot with antibodies to the corresponding tags. The presence of CRIPT-derived PDZ~3~ ligands in the lysate had almost negligible effect on PSD-95 GKAP interaction.\
10.7554/eLife.41299.014Figure 5---source data 1.Source data for [Figure 5](#fig5){ref-type="fig"}.](elife-41299-fig5){#fig5}

We next tested whether the GKAP - PSD-95 association could be influenced by CRIPT-derived PDZ~3~ ligands that bind to PSD-95, as we observed previously for Gnb5 (see [Figures 4A, B](#fig4){ref-type="fig"} and [5B](#fig5){ref-type="fig"}). The presence of PDZ~3~ ligands did not substantially influence the GKAP interaction: PSD-95 binds GKAP regardless of whether wild-type or mutant CRIPT-derived PDZ~3~ ligands were present ([Figure 5C](#fig5){ref-type="fig"}). These data provide further evidence that the GKAP - GK domain binding mode differs substantially from the Gnb5 - GK interaction mode.

Importantly, our data support a model in which ligand binding to PDZ~3~ results in a conformational change of the 'resting' intramolecular SH3-GK interaction that is common to MAGUK proteins. This conformational alteration is reflected by a change in the availability of specific GK surfaces for protein-protein interactions ([Figure 6A](#fig6){ref-type="fig"}). In the resting state, the external GK surface harbouring the classical GMP binding site is available for protein-protein interaction such as those with the well-known PSD-95 interactors GKAP and MAP1a. However, upon ligand binding, other GK surfaces become accessible for protein-protein interactions. A subset of synaptic GK-interacting proteins -- in particular Gnb5, and perhaps other proteins enriched in our pool of interacting proteins that bind preferentially to GK rather than to SH3-GK -- bind to these surfaces of the GK domain ([Figure 6B](#fig6){ref-type="fig"}).

![Graphical Summary.\
(**A**) PSD-95 C-terminal domains (PSG module) functionally cooperate and regulate homotypic and heterotypic complex formation. We propose that CRIPT-derived PDZ~3~ ligand binding to the PDZ~3~ domain induces a loosening of the intramolecular SH3-GK interaction. This 'open' conformation is then able to initiate subsequent oligomerisation and protein binding. (**B**) Model of CRIPT-derived PDZ~3~ ligand-dependent and ligand-independent binding to the PSD-95 C-terminal SH3-GK domain tandem. Ligand - PDZ~3~ domain binding facilitates association with Gnb5.](elife-41299-fig6){#fig6}

Discussion {#s3}
==========

The molecular basis for the dynamic regulation of synaptic transmission is dependent on the assembly and disassembly of protein complexes ([@bib50]; [@bib21]). It is also well established that activity-dependent changes in synaptic protein networks depend on phosphorylation ([@bib31]; [@bib1]; [@bib23]) and other post-translational modifications, such as palmitoylation ([@bib9]; [@bib12]). Recently, it has been reported that the minimal requirement for the amplification of synaptic signals is the interaction of glutamate receptor auxiliary subunits with postsynaptic scaffold proteins; specifically the interaction between different PDZ ligand C-termini and synaptic MAGUKs can trigger a common molecular mechanism necessary for the induction of long-term potentiation downstream of glutamate receptors ([@bib39]).

In this study, we focussed on the postsynaptic scaffold protein PSD-95, which plays a central role in activity-dependent synapse regulation ([@bib7]). It is established that protein complex formation guided by PSD-95 PDZ and GK domains can be reversibly regulated by phosphorylation ([@bib42]; [@bib57]), and at postsynaptic membranes, various PDZ ligand C-termini of multimeric receptor complexes are available to form multivalent interactions with scaffold proteins ([@bib38]). In previous work, we showed that binding of CRIPT-derived ligands to PDZ~3~ of PSD-95 promoted formation of PSD-95 multimers ([@bib34]). More recently, it was shown by others that binding of a SynGAP-derived PDZ ligand peptide was sufficient to induce PSD-95 PSG construct dimerisation ([@bib51]), and the same group subsequently explored how SynGAP-induced conformational coupling between the PDZ~3~ domain and the SH3-GK module plays a role in this process ([@bib52]).

Here we identify synaptic interactors whose association with PSD-95 is influenced by the conformational state of the PSD-95 C-terminus. Among these proteins, we focussed further on Gnb5. Gnb5 acts in a heterodimeric complex together with RGS7 to functionally couple GIRK channels to GABA~B~ receptors ([@bib48]; [@bib33]). Upon activation of GABA~B~ receptors, the Gnb5-RGS7 complex promotes fast deactivation of GIRK channels ([@bib10]). Interestingly, the interaction between RGS proteins and Gnb5 involves the N-terminal helical domain of Gnb5 and the G protein gamma-subunit-like (GGL) domain of RGS proteins ([@bib4]). In our experiments, the protein complex formation between PSD-95 and Gnb5 likewise involved the N-terminal helix of Gnb5: its deletion (see shortGnb5) strongly inhibited the interaction with PSD-95. It will be interesting to explore if PSD-95 competes with RGS7 for Gnb5 interaction during GABA~B~ -- GIRK channel signalling, or if PSD-95 associates with a different pool of Gnb5 that acts in other processes.

Our data indicate that the Gnb5 - PSD-95 interaction is positively regulated by ligand binding to the third PDZ domain of PSD-95. In order to understand how this occurs, it is important to note that in MAGUK scaffold proteins, the SH3 and GK domains interact directly, and together they form a unique structure that sets them apart from SH3 and GK domains found independently in other protein families ([@bib44]). Indeed, PSD-95 SH3 and GK domains, when expressed independently, bind each other efficiently ([@bib28]; [@bib41]). Likewise, in line with this structural model, mutations that disrupt the interface where these two domains contact each other can have detrimental effects on protein function ([@bib28]; [@bib41]). Also relevant is the fact that the SH3 domain has been reported to be an allosteric regulator or inhibitor of GK domain binding function, not only by direct contact with the adjacent GK surface but also by regulating the conformation of distant GK domain surfaces ([@bib26]). It is possible that binding of a ligand to the PSD-95 PDZ~3~ domain influences precisely this function of the neighbouring SH3 domain and thus indirectly regulates GK interactions at distant sites. Alternatively, it is conceivable that regulation via PDZ~3~ ligand binding results in a conformational change that loosens the natural SH3-GK structure, thereby freeing up the SH3-interacting surface of the GK domain for other protein-protein interactions. Nevertheless, in both possible scenarios, binding of a ligand to the adjacent PDZ~3~ domain would release the GK domain from its regulation by the interacting SH3 domain. In order to explore these two possibilities, we took advantage of the established GK interactor GKAP and we compared Gnb5 and GKAP with regard to PSD-95 binding. By introducing a mutation (R568A) in the canonical GMP-binding region of PSD-95, we were able to completely abolish GKAP binding to the PSD-95 GK domain. The GKAP - PSD-95 interaction, however, was not influenced by ligand binding to PDZ~3~. This result suggests that the canonical GMP-binding region in the GK domain is *not* allosterically regulated by PDZ~3~ ligand binding. For Gnb5, we observed the opposite pattern: First of all, the R568A mutation had no effect on the Gnb5 - PSD-95 interaction, suggesting that Gnb5 might occupy a different GK domain surface for interaction -- one that does not directly overlap with the canonical GMP-binding site responsible for the GKAP interaction. Second, the Gnb5 - PSD-95 association, unlike the GKAP - PSD-95 interaction, is strongly dependent on ligand binding to PDZ~3~, which provides further support for the idea that Gnb5 binds the PSD-95 GK domain away from the GMP-binding site.

We propose that the Gnb5 - PSD-95 interaction is regulated by a modular allosteric mechanism: the SH3 domain exerts inhibitory activity on the GK domain binding capacity by competing directly with Gnb5 for interaction surfaces. Our data are in line with a model in which the PSD-95 SH3-GK domain tandem undergoes structural rearrangements upon binding of a CRIPT-derived PDZ~3~ ligand to the adjacent PDZ~3~ domain, and these changes free up the GK domain for interactions with selected proteins.

Our study highlights three interesting avenues for further study. Exploring how Gnb5 functionally links PSD-95 to GIRK channels, as discussed above, is of primary interest. In addition, the idea that other MAGUKs might be subject to similar ligand-induced alterations and subsequent modulation of protein interactions is relevant. Data from other groups suggest that SynGAP, which also binds to PSD-95 PDZ~3~, specifically influences conformational coupling between PDZ~3~ and the SH3-GK module, while the related SAP102 does not undergo the same mechanistic alterations ([@bib52]). It will be interesting to explore if the intramolecular SH3-GK assembly of synaptic MAGUKs is generally regulated by ligand binding to PDZ~3~, as we observe for PSD-95. It is likewise of interest to investigate in more detail how different PDZ~3~-binding ligands compare to full-length CRIPT and NLGN1 in how they induce changes within the SH3-GK assembly of PSD-95, and how these changes influence homotypic and heterotypic PSD-95 complex formation. The temporal and spatial expression of PDZ~3~-binding proteins could potentially steer the formation and composition of specific PSD-95-associated complexes. Moreover, kinase-mediated signalling in response to changes in synaptic activity can also influence binding affinity of ligands for PDZ~3~ domains ([@bib45]), highlighting another mechanistic level at which PSD-95 complex formation can be regulated by biological processes. These ideas will be explored in future investigations.

Materials and methods {#s4}
=====================

DNA constructs {#s4-1}
--------------

Full-length rat PSD-95 (NM_019621) was cloned into pCMV-Tag3A, to obtain MYC-PSD-95. Arginine 568 was exchanged to Alanine by site-directed mutagenesis to generate MYC-PSD-95 R568A.

PSD-95-YN was generated by a PCR based strategy: amino acids 1--724 of PSD-95 were fused to a flexible 3x(GGGGS) linker followed by amino acids 1--154 of EYFP and an HA-tag. PSD-95-YC was generated accordingly by fusing amino acids 1--724 of PSD-95 to a flexible 3x(GGGGS) linker followed by amino acids 155--238 of EYFP and a MYC-tag. Leucine 460 was exchanged to proline by site-directed mutagenesis to generate PSD-95-YN L460P.

MYC-PSG was generated by cloning a fragment that encodes amino acids 247--724 of PSD-95 into pCMV-Tag3A. MYC-PSG L460P and MYC-PSG R568A were generated by PCR based site-directed mutagenesis. FLAG-SH3-GK and FLAG-GK constructs were generated by cloning fragments that encode amino acids 403--724 (SH3-GK) and amino acids 504--724 (GK) of PSD-95 into pCMV-Tag2A. MYC-GK was generated by cloning a fragment that encodes amino acids 504--724 of PSD-95 into pCMV-Tag3A.

GST-SH3-GK and GST-GK constructs were generated by cloning fragments that encode amino acids 403--724 (SH3-GK) and amino acids 504--724 (GK) of PSD-95 into pGEX-6P-1 (GE Healthcare).

Full-length rat Neuroligin-1 (NLGN1, NM_053868.2) was cloned into pcDNA3.1 and an HA-tag (YPYDVPDYA) was inserted following the signal sequence (between amino acid 45 and 46) by PCR mutagenesis. The C-terminal PDZ ligand motif (TTRV) was mutated to abolish PDZ domain binding by introducing two alanine residues (T**A**R**A**) to generate a mutNLGN1 construct.

Full-length rat SynCAM1 (XM_006242948) was cloned into pCMV-Tag2A and an HA-tag (YPYDVPDYA) was inserted following the signal sequence (between amino acid 47 and 48) by PCR mutagenesis.

CRIPT-derived PDZ~3~ ligand constructs were generated by fusing an HSV-tag (QPELAPEDPED) to mCherry followed by a flexible 3x(GGGGS) linker and 10 amino acids (DTKNYKQTSV) referring to the PDZ ligand CRIPT. MutPDZ ligand constructs were generated by mutating the C-terminal QTSV motif to Q**A**S**A**.

Full-length rat Gnb5 (NM_031770) was cloned into pCMV-Tag2A to generate FLAG-Gnb5. A shortGnb5 construct was generated by cloning a fragment that encodes amino acids 34--353 of Gnb5 into pCMV-Tag2A. Gnb5-Clover was generated by cloning Gnb5 into pEYFP-N1. In a subsequent cloning step EYFP was exchanged for Clover. Full-length mouse GKAP (NM_001360665) was cloned into pCMV-Tag2A to generate FLAG-GKAP.

Cell culture and transfection {#s4-2}
-----------------------------

COS-7 (DSMZ no. ACC 60) and HEK-293T (DSMZ no. ACC 635) cells were purchased from the Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. HEK-293T (DSMZ no. ACC 635) cell identity was confirmed by fluorescent nonaplex PCR of short tandem repeat markers by DSMZ. COS-7 (DSMZ no. ACC 60) cell identity was confirmed by Hinf I-(gtg)~5~ DNA profiling by DSMZ. Both cell lines were tested negative for mycoplasma. Cultured cells were maintained in DMEM containing 10% FBS, PEN-STREP (1000 U/ml) and 2 mM L-glutamine. Cells were transfected with Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's protocol and harvested for subsequent experimental procedures 20--24 hr post transfection.

Bimolecular fluorescence complementation (BiFC) assay and flow cytometry {#s4-3}
------------------------------------------------------------------------

HEK-293T cells were cultured in 12 well plates and transfected with the respective expression construct combinations. Prior to analysis by flow cytometry (BD FACS Calibur) the cells were incubated for 60 min at room temperature to promote fluorophore formation. Cells were harvested by gently rocking the culture dishes and washing with PBS/10% FBS. The HEK-293T cell population was identified in the forward vs. side scatter plot and a gate was defined for subsequent analyses. 10,000 single-cell events for each construct combination were measured and fluorescence was quantified (BD CellQuest and FlowJo).

Coimmunoprecipitation {#s4-4}
---------------------

Transfected COS-7 cells were harvested 20--24 hr post transfection, resuspended in lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 0.1% NP40, pH 7.5/1 ml per T75 flask) and lysed using a 30-gauge syringe needle. Lysates (1 ml) were cleared by centrifugation and incubated with 2 µg of the appropriate antibody (mouse αGFP antibody \[Roche\], mouse αMYC \[Clontech\], or normal mouse IgG \[Santa Cruz\]) for 3 hr followed by a centrifugation at 20,000 x *g*. Supernatants were incubated with 30 µl Protein G-Agarose (Roche) per ml and washed three times with lysis buffer.

Western blot {#s4-5}
------------

Immunocomplexes were collected by centrifugation, boiled in SDS sample buffer, and separated by 10% Tricine-SDS-PAGE ([@bib37]). Proteins were blotted onto a PVDF membrane (0.2 µm pore size, Bio-Rad) by semidry transfer (SEMI-DRY TRANSFER CELL, Bio-Rad). Membranes were blocked (PBS/0.1% Tween 20/5% dry milk) and incubated overnight with the primary antibody (1:5000). After incubation with the respective horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000), blots were imaged using chemiluminescence HRP substrate (Western Lightning Plus ECL, Perkin Elmer) and a luminescent image analyser (ImageQuant LAS 4000 mini, GE Healthcare). The following primary antibodies were used for protein detection: αFLAG M2-HRP (mouse, A8592, Sigma), αGnb5 (rabbit, ab185206, Abcam), αMYC (rabbit, 2272S, Cell Signalling). Secondary antibodies: αMouse-HRP (115-035-003, Dianova), αRabbit-HRP (111-035-003, Dianova). All western blots shown are representative results from individual pull-down experiments that have been replicated at least three times with similar outcome.

For western blot quantification, coIP band intensities were measured with the ImageQuant TL 1D v8.1 software (GE Healthcare). In each lane, the band detection areas were set to the same size and the background was automatically corrected using the 'rubberband' method. The resulting band volumes (total sum of pixel intensities) were normalised within each experiment to the respective internal control lane and the results represent relative fold changes (mean ±SEM). For a quantitative view of the variations between individual experiments, the resulting values of three experiments were combined and represented as dot plots.

Isolation of proteins from the crude synaptosome fraction and GST pull-down {#s4-6}
---------------------------------------------------------------------------

One rat brain (Wistar, 2 g) was used to isolate the crude synaptosome fraction with Syn-PER reagent (Thermo Scientific) according to the manufacturer's manual. In brief, one rat brain was homogenised in 20 ml Syn-PER with a Dounce tissue grinder on ice. The resulting homogenate was centrifuged at 4°C for 10 minutes / 1200 x *g*. The supernatant was transferred to a new centrifuge tube and centrifuged at 4°C for 20 minutes / 15,000 x *g*. The resulting crude synaptosome pellet was solubilised in 10 ml PBS/1% Triton X-100 and cleared by centrifugation.

GST-GK and GST-SH3-GK constructs were expressed in *E.coli* BL21 DE3 and purified according to the manufacturer's manual (GST Gene Fusion System, GE Healthcare). 30 µl of glutathione agarose (Pierce) was loaded with GST-GK or GST-SH3-GK proteins and incubated for 3 hr with solubilised proteins. The beads were washed three times with PBS/1% Triton X-100 and further processed for SDS-PAGE.

Sample preparation and liquid chromatography-mass spectrometry (LC-MS) {#s4-7}
----------------------------------------------------------------------

Proteins were eluted from the matrix by incubation with SDS sample buffer for 5 min at 95°C and subsequently separated by SDS-PAGE (10% Tricine-SDS-PAGE). Coomassie-stained lanes were cut into 12 slices and in-gel protein digestion and ^16^O/^18^O-labeling was performed as described previously ([@bib18]; [@bib20]). In brief, corresponding samples were incubated overnight at 37°C with 50 ng trypsin (sequencing grade modified, Promega) in 25 μl of 50 mM ammonium bicarbonate in the presence of heavy water (Campro Scientific GmbH, 97% ^18^O) and regular ^16^O-water, respectively. To prevent oxygen back-exchange by residual trypsin activity, samples were heated at 95°C for 20 min. After cooling down, 50 μl of 0.5% TFA in acetonitrile was added to decrease the pH of the sample from \~8 to \~2. Afterwards, corresponding heavy- and light-isotope samples were combined and peptides were dried under vacuum. Peptides were reconstituted in 10 μl of 0.05% (v/v) TFA, 2% (v/v) acetonitrile, and 6.5 µl were analysed by a reversed-phase capillary nano liquid chromatography system (Ultimate 3000, Thermo Scientific) connected to an Orbitrap Velos mass spectrometer (Thermo Scientific). Samples were injected and concentrated on a trap column (PepMap100 C18, 3 μm, 100 Å, 75 μm i.d. ×2 cm, Thermo Scientific) equilibrated with 0.05% TFA, 2% acetonitrile in water. After switching the trap column inline, LC separations were performed on a capillary column (Acclaim PepMap100 C18, 2 μm, 100 Å, 75 μm i.d. ×25 cm, Thermo Scientific) at an eluent flow rate of 300 nl/min. Mobile phase A contained 0.1% formic acid in water, and mobile phase B contained 0.1% formic acid in acetonitrile. The column was pre-equilibrated with 3% mobile phase B followed by an increase of 3--50% mobile phase B in 50 min. Mass spectra were acquired in a data-dependent mode utilising a single MS survey scan (m/z 350--1500) with a resolution of 60,000 in the Orbitrap, and MS/MS scans of the 20 most intense precursor ions in the linear trap quadrupole. The dynamic exclusion time was set to 60 s and automatic gain control was set to 1 × 10^6^ and 5.000 for Orbitrap-MS and LTQ-MS/MS scans, respectively.

Proteomic data analysis {#s4-8}
-----------------------

Identification and quantification of ^16^O/^18^O-labelled samples was performed using the Mascot Distiller Quantitation Toolbox (version 2.6.3.0, Matrix Science). Data were compared to the SwissProt protein database using the taxonomy *rattus* (August 2017 release with 7996 protein sequences). A maximum of two missed cleavages was allowed and the mass tolerance of precursor and sequence ions was set to 10 ppm and 0.35 Da, respectively. Methionine oxidation, acetylation (protein N-terminus), propionamide (C), and C-terminal ^18^O~1~- and ^18^O~2~-isotope labeling were used as variable modifications. A significance threshold of 0.05 was used based on decoy database searches. For quantification at protein level, a minimum of two quantified peptides was set as a threshold. Relative protein ratios were calculated from the intensity-weighted average of all peptide ratios. The median protein ratio of each experiment was used for normalisation of protein ratios. Only proteins that were quantified in all three replicates with a standard deviation of \<2 were considered. Mean protein L/H ratios (GST-GK/GST-SH3-GK) from all three replicates were calculated. Known contaminants (e.g. keratins) and the bait protein were removed from the protein output table.

Live cell microscopy {#s4-9}
--------------------

HEK-293T cells were seeded in 35 mm FluoroDishes (World Precision Instruments) and triple-transfected with PSD-95-YN, PSD-95-YC and Neuroligin-1 expression constructs. Images were acquired using a spinning disk confocal microscope (Nikon CSU-X).

Immunofluorescence and confocal microscopy {#s4-10}
------------------------------------------

Mixed cultures of primary hippocampal neurons were generated as reported earlier ([@bib35]). Briefly, E18 Wistar pups were decapitated, and hippocampi were isolated and collected in ice-cold DMEM (Lonza). Single cell solution was generated by partially digestion (5 min at 37°C) with Trypsin/EDTA (Lonza). The reaction was stopped by adding DMEM/10% FBS (Biochrom) following a subsequent washing with DMEM. Tissue was then resuspended in neuron culture medium (Neurobasal supplemented with B27 and 500 μM glutamine) and mechanically dissociated. Neurons were plated at \~10^5^ cells/cm^2^ on coverslips coated with poly-D-Lysine and laminin (Sigma). One hour after plating, cell debris was removed and cultures were maintained in a humidified incubator at 37°C with 5% CO~2~. The hippocampal neurons were fixed at DIV21 with 4% PFA in PBS for 10 min at RT and permeabilised with 0.2% Triton-X in PBS for 5 min. After blocking for 1 hr at RT with blocking solution (4% BSA in PBS) the primary antibodies were incubated overnight at 4°C diluted 1:500 in blocking solution. Secondary antibodies were diluted 1:1000 in blocking solution and incubated for 1 hr at RT. Coverslips were mounted with Fluoromount G and images were acquired with a Leica laser-scanning confocal microscope (Leica TCS-SP5 II, 63x objective). Primary antibodies: αGnb5 (rabbit, ab185206, Abcam), αPSD-95 (mouse, 75--028, NeuroMab), αMAP2 (mouse, 05--346, Millipore), αMAP2 (guinea pig, 188004, Synaptic Systems), αSynapsin (guinea pig, 106004, Synaptic Systems). Secondary antibodies: αRabbit Alexa Fluor 488 (A-21441, Invitrogen), αGuinea pig Alexa Fluor 568 (Thermo Fisher), αGuinea pig Alexa Fluor 405 (ab175678, Abcam), αMouse Alexa Fluor 568 (A-11031, Life Technologies), αMouse Alexa Fluor 405 (A-31553, Invitrogen).

Laboratory animal handling {#s4-11}
--------------------------

All animals used were handled in accordance with the relevant guidelines and regulations. Protocols were approved by the 'Landesamt für Gesundheit und Soziales' (LaGeSo; Regional Office for Health and Social Affairs) in Berlin and animals reported under the permit number T0280/10.
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Thank you for submitting your article \"Intramolecular domain dynamics regulate synaptic MAGUK protein interactions\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Matthieu Sainlos (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this study the authors build on earlier studies by themselves and others showing that binding of ligands to the third PDZ domain of PSD-95 changes the conformation of the SH3-GK domain. Other studies have shown that a portion of the GK domain becomes more exposed upon binding of ligands to PDZ3, and this appears to increase the probability of formation of PSD-95 dimers by \"domain-swapping.\" The new finding in this study is that opening up of the GK domain exposes binding sites for additional proteins to the GK site. The authors carry out a \"proteomic\" study to identify possible interacting proteins that bind to the GK site alone but not to the tandem SH3-GK domain. They identify several G-protein subunits as potential regulated binders, and follow up with a study of the binding of gnb5, a β subunit that is known to activate GIRK channels downstream of GABAB receptors. They confirm that this interaction is regulated by binding of a PDZ domain ligand and that it does not require a critical arginine residue in the GK binding groove (unlike a characterized GK partner, GKAP). These results indicate that there are at least two different binding modes in place for the GK domain. This study is interesting for two reasons. It identifies a regulated binding site on the GK domain of PSD-95 that is apparently blocked by interaction with the SH3 domain in the monomeric form of PSD-95. The study shows that gnb5 can bind to this site, suggesting that PSD-95 may, under particular conditions, localize gnb5 near synaptically located GABAB receptors at excitatory synapses, possibly increasing the probability of regulation of GIRK channels by nearby release of GABA.

Essential revisions:

There are some major concerns that must be addressed before the study can be published in *eLife*.

1\) In most of the figures, results are shown as single immunoblots without quantification, an indication of how often they were reproduced, or the size of the standard error. In general it is not clear how often each individual experiment was repeated. This should clearly be stated for each figure. Quantification and statistical measures over several experiments are necessary for all of these instances in order to ensure the reproducibility and rigor of the findings before they can be published in *eLife*.

2\) Figure 1 lacks at least one critical control. The authors need to show and quantify the fluorescent signal When WT/WT split EYFP and WT/L460 split EYFP are expressed without a PDZ binding ligand. In the absence of this control it is not possible to assess with confidence the size of the effect of a PDZ ligand. The mutNLGN1 is an important control, but it is not adequate by itself. In addition, in Figure 1C, mutating the NLGN1 ligand for PDZ3 reduces signal by only \~40%. The mutation of the TTRV sequence to TARA would be expected to mostly if not completely abrogate binding of this ligand to PDZ3. If so then there should be a nearly 100% loss of the signal. The authors need to address to which degree the TARA really reduces binding and, if it is a complete abrogation, explain why the effect in that experiment is only partial. Also, Shin et al., 2000, as cited) find that the L460P mutation does not prevent multimerization of PSD-95 in contrast to what appears to be the case in Figure 1C. The authors need to address this discrepancy. In fact, the authors conclude later that the open conformation (as would be induced by either binding of ligand to PDZ3 or the L460P mutation) is required for binding of Gnb5. Why the L460P mutation does not result in any multimerization of PSD-95 in Figure 1C is unclear.

3\) The authors tend to overgeneralize/lack precision on some key elements. Their initial article (Rademacher et al., 2013) only showed that PSD-95 and not synaptic MAGUK proteins oligomerized upon PDZ domain ligand binding. Other reports indicate different behavior within the PSD-95 family with respect to oligomerization (Zeng et al., 2018 -- and not 2017). Similarly, the authors often use the term PDZ3 ligand leading the reader to believe that any PDZ3 ligand will have the same effect. However they have only used two ligands -CRIPT and Neuroligin- and again other reports indicate a difference between CRIPT and another PDZ3 ligand, SynGAP, on their effect on the PSG module (Zeng et al., 2018). Of note, the molecular mechanism by which SynGAP interaction leads to PSD-95 oligomerization is clearly presented in that same study, despite what is written in the discussion (referring to an older citation).

4\) Along these lines, considering that CRIPT and SynGAP led to different results for PSD-95 oligomerization in Zeng et al., 2018, it would be interesting to clarify how the present results compare to the one obtained with the SynGAP PDZ3 ligand. Another point is that while CRIPT is, to my knowledge, a monomer, full-length Neuroligin is a dimer which complicates the interpretation of the results of the first section and raises the question if the same oligomerization mechanism is observed.

5\) The claim that Gnb5 and GKAP occupy different subdomains is not supported by totally convincing data. The results clearly show a different mode of interaction but do not exclude the fact that it could be the same subdomain. Simultaneous co-precipitation of the two GK partners, if successful, could support such a claim.

6\) The method that the authors use to isolate \"synaptic proteins\" using a reagent sold by Thermo-Fisher has not been verified in any peer-reviewed publication. A search of the online references listed on the Thermo-Fisher website does not contain any method that can reliably enrich for synaptic proteins without the use of a density gradient. The inadequacy of the method is revealed, for example, by the high level of ribosomal proteins listed in the author\'s Figure 2---source data 1. In subsection "The SH3-GK assembly state influences PSD-95 interactions with synaptic proteins", the authors cite the overlap between their list of proteins and that of Wilkinson et al., 2017. However, Wilkinson et al. did not use a method that enriches for synaptic proteins. They simply extracted a crude membrane pellet from a brain homogenate with detergent to obtain detergent insoluble proteins. The extracted pellet would contain microsomes and mitochondria, in addition to synaptosomes. This fraction is not a postsynaptic density fraction because it skips the step of isolating synaptosomes from the brain homogenate. For the continued integrity of the literature, the authors should eliminate statements that indicate that they are working with \"synaptic proteins\" or \"postsynaptic density\" proteins. They should eliminate the reference to the Wilkinson paper completely as it does not support their statement that they are working with synaptic proteins. The authors have wisely chosen to work with a protein that has been shown to be located in the excitatory postsynaptic compartment, and to play an important role there (regulation of GIRK channels by GABAB receptors). They have verified the synaptic location of the particular protein they have studied. Nonetheless, all claims to have started with anything other than a detergent insoluble extract of a crude brain membrane fraction should be removed.

7\) There is not enough information in the Materials and methods section about how flow cytometry was performed and no actual plots of data distribution are shown as would be customary for such analysis, including the presumed existence of various populations of cells. Did the authors stain for cell viability (like propidium iodide) to exclude defective cells?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Intramolecular domain dynamics regulate synaptic MAGUK protein interactions\" for further consideration at *eLife*. Your revised article has been favourably evaluated by Richard Aldrich (Senior Editor), and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

In this first revision, the authors have responded adequately to some, but not all of the major comments on the original manuscript. They have included quantitation and statistical analysis of all of their experiments as appropriate. They have included a new control (SynCAM1) in their transfections to strengthen the conclusion that the interaction of the two halves of EYFP fused to neuroligin and transfected into 293 cells requires interaction of neuroligin with a PDZ domain of PSD-95.

However, the authors have not responded adequately to the criticism that they have over-generalized and lack precision in their writing. There are two aspects of this problem.

1\) The authors conflate the finding that the CRIPT 10-mer \"opens-up\" the GK domain exposing a new domain that binds to Gnb5, with the generalization that the CRIPT 10-mer promotes multimerization of PSD-95 (which they believe also leads to dimerization of tagged neuroligin). The implication is that the multimerization of PSD-95 arises from the \"opening up\" of the GK and SH3 domains so that they can interact in trans with other proteins. This generalization conflicts with the finding reported by Zeng et al. in Journal of Molecular Biology (2018) that binding of a peptide containing the final 17 residues of CRIPT (CRIPT 17-mer) to PDZ3 does NOT lead to multimerization of PSD-95; whereas binding of a peptide containing the final 15 residues of synGAP DOES result in multimerization of PSD-95.

Communication about this issue may have been obfuscated by the fact that the authors have mis-stated the year of this Zeng et al. publication as 2017. The authors need to fix the citation of the J. Mol. Bio. paper by Zeng et al. by changing the year to 2018. Note that a later Cell paper published by Zeng et al. in 2018 on a similar topic is actually not relevant to the present study and should not be cited.

In the Zeng et al. 2018 J. Mol. Biol. paper, Zeng et al. used size-exclusion chromatography and NMR to show that binding of the synGAP 15-mer to PDZ3 (including a short downstream α helix) causes dimerization of the PSD-95 construct; whereas, binding of the CRIPT 17-mer does not cause dimerization of PSD-95. The reviewers can think of two possible reasons for the discrepancy between their results and the present manuscript. One is that Zeng et al. used a CRIPT 17-mer; whereas the present authors used a CRIPT 10-mer. Perhaps the two peptides produce different results with respect to \"opening-up\" of the GK domain. If this is the case, it calls into question the in vivo significance of the finding with the CRIPT 10-mer. The other possible explanation is that the binding of either of the two CRIPT peptides to PDZ3 of PSD-95 causes a change in conformation of the SH3-GK domains such that a new binding site for Gnb5 and other proteins is made available; however, the conformational change does not permit full dimerization of PSD-95 through the domain-swapping trans association. In other words, CRIPT peptides may produce a different change in the structure of the SH3-GK domain than does the synGAP 15-mer. In the present manuscript, the authors have not used any methodology that would directly detect dimerization of the PSD-95 construct by the domain-swapping trans interaction. They have assumed that fluorescence resulting from interaction of the two halves of EYFP linked to neuroligin results from oligomerization of PSD-95. For example, they state:

\"In this study, we use a bimolecular fluorescence complementation (BiFC) assay to show that PSD-95 oligomerisation is triggered by PDZ3 ligands and dependent on the C-terminal SH3-GK domain tandem.\"

To resolve the apparent conflict between their data and that of Zeng et al., the authors should compare the effect of a CRIPT 17-mer in their assays to the effect of the CRIPT 10-mer and test directly for dimerization of the PSD-95 construct after binding of the peptides by size-exclusion chromatography or another method that would unambiguously detect dimerization of PSD-95.

2\) The authors continue to inappropriately generalize their results to all PDZ3 binding ligands. For example:

In the Abstract, \"Here we show that binding of monomeric PDZ3 ligands to the third PDZ domain of PSD-95 induces functional changes in the intramolecular SH3-GK domain assembly that influence subsequent homotypic and heterotypic complex formation.\"

\"...this interaction is triggered by PDZ3 ligands binding to the third PDZ domain of PSD-95,...\"

Introduction section: We have previously shown that synaptic MAGUK proteins oligomerise upon binding of monomeric PDZ3 ligands (ligands that specifically bind to the third PDZ domain) (Rademacher et al., 2013) and speculated that ligand -- PDZ3 domain binding induces conformational changes in the C-terminal domains that lead to complex formation.\"

This generalization to all PDZ3 ligands is repeated in several places in the manuscript. The authors should replace the term PDZ3 ligand with the name of the specific ligand that the authors use in each experiment.

10.7554/eLife.41299.019

Author response

> Essential revisions:
>
> There are some major concerns that must be addressed before the study can be published in eLife.
>
> 1\) In most of the figures, results are shown as single immunoblots without quantification, an indication of how often they were reproduced, or the size of the standard error. In general it is not clear how often each individual experiment was repeated. This should clearly be stated for each figure. Quantification and statistical measures over several experiments are necessary for all of these instances in order to ensure the reproducibility and rigor of the findings before they can be published in eLife.

All immunoblots in the Results section of the revised manuscript (Figures 1E, 3A, 3B, 4A, 4B, 4C, 5A, 5B, and 5C) show the results of representative experiments that were performed with identical conditions three times. As recommended by the reviewers, we quantified the 3 experiments and calculated mean intensities plus standard error and included these results as dot plots within the main figures. We have modified the figure legends accordingly and described the quantification procedure in detail in the Materials and methods section. The measured band intensities (original data) are now included as a supplemental table.

> 2\) Figure 1 lacks at least one critical control. The authors need to show and quantify the fluorescent signal When WT/WT split EYFP and WT/L460 split EYFP are expressed without a PDZ binding ligand. In the absence of this control it is not possible to assess with confidence the size of the effect of a PDZ ligand. The mutNLGN1 is an important control, but it is not adequate by itself. In addition, in Figure 1C, mutating the NLGN1 ligand for PDZ3 reduces signal by only \~40%. The mutation of the TTRV sequence to TARA would be expected to mostly if not completely abrogate binding of this ligand to PDZ3. If so then there should be a nearly 100% loss of the signal. The authors need to address to which degree the TARA really reduces binding and, if it is a complete abrogation, explain why the effect in that experiment is only partial.

Indeed these are relevant points and we have addressed them in the revised manuscript. Comparing refolding of splitEYFP halves in the presence and absence of NLGN1 (which involves comparison of a triple transfection with a double transfection) is problematic; PSD-95-splitEYFP expression levels change when there is no third molecule present, thereby making results difficult to compare with those following double transfection. We have therefore designed a more suitable control, in which we substitute NLGN1 with a comparable amount of SynCAM1 DNA in the transfection. SynCAM1, like NLGN1, is a synaptic cell adhesion molecule, but unlike NLGN1, is not able to bind to PSD-95 (Biederer et al., 2002). Instead, it binds to other MAGUKs, including e.g. CASK and MPP2, which harbour class II ligand-binding PDZ domains rather than class I ligand-binding PDZ domains. In an additional set of experiments (done in triplicate and repeated 4 times, as all of our FACS analyses are performed), we have included this control (see new Figure 1C). As expected, SynCAM1 is unable to induce PSD-95 complex formation and subsequent EYFP refolding.

Regarding our mutant NLGN1 control: It is indeed likely that we do not have 100% abrogation of binding to PSD-95 with the TARA mutant, which would explain why we still see significant EYFP refolding of PSD-95-splitEYFP halves in the presence of the NLGN1 molecule with mutations in the PDZ binding motif. This idea is supported by our new Figure 1C, in which we compare the effects of wild-type NLGN1 with that of the synaptic cell adhesion molecule SynCAM1 (described above). In particular for PDZ ligands that have substantial cytosolic sequences (as is the case for NLGN1), it is likely that residues outside of the C-terminal PDZ binding motif influence ligand-PDZ domain binding and/or stability. For several ligand-PDZ domain interactions, including e.g. SynGAP/PSD-95 (Walkup et al., 2016) and Crumbs/PALS1 (Li et al., 2014), this is clearly the case; we expect that related phenomena also apply in the case of NLGN1.

> Also, Shin et al., 2000, as cited, find that the L460P mutation does not prevent multimerization of PSD-95 in contrast to what appears to be the case in Figure 1C. The authors need to address this discrepancy. In fact, the authors conclude later that the open conformation (as would be induced by either binding of ligand to PDZ3 or the L460P mutation) is required for binding of Gnb5. Why the L460P mutation does not result in any multimerization of PSD-95 in Figure 1C is unclear.

Shin et al. (Shin et al., 2000) showed that PSD-95 L460P mutant proteins associate with membranes and interact with the potassium channel Kv1.4 (via PDZ domain interactions) indistinguishable from wild-type PSD-95. These results resemble our own observations regarding the subcellular localisation and PDZ-binding properties of PSD-95 L460P (see e.g.(Rademacher et al., 2013)). However, the L460P mutant proteins fail to cluster the Kv1.4 channels in their clustering assay, an interesting observation that is in line with our FACS results in Figure 1, where this single amino acid exchange in the C-terminal SH3 domain also interferes with higher order protein complex formation. In their study, Shin et al. additionally use a coimmunoprecipitation assay to explore PSD-95 multimerisation. In this part of their study, however, they do not investigate the behaviour of full-length PSD-95, which explains why their resulting conclusions differ from ours. Shin et al. demonstrate that the PSD-95 L460P mutant associates efficiently with a short N-terminal PSD-95 variant containing what they refer to as "the N-terminal multimerization domain" (N-PSD-GFP, which consists exclusively of the N-terminal 64 amino acids of PSD-95 fused to GFP); this experiment is not comparable to our FACS assay with full-length PSD-95 variants.

It is perhaps important to point out here that since the study by Shin et al. was published in 2000, it has become clear that this N-terminal region is not the main element involved in PSD-95 multimerisation. Shortly afterwards, McGee et al., 2001, highlighted a different multimerisation mechanism that relies on the C-terminal SH3-GK module (McGee et al., 2001), and our own work (e.g. (Rademacher et al., 2013)), as well as that of other groups (Zeng et al., 2016; Zeng et al., 2017) likewise focusses on multimerisation mechanisms that involve the SH3-GK module instead of the N-terminus of PSD-95. As we point out in the manuscript, the L460P mutation abolishes the intramolecular reaction between the SH3 and GK domains (McGee and Bredt, 1999), and thereby prevents the SH3 domain from interacting with the GK domain in both intra- and intermolecular PSD-95 interactions, thus negatively influencing well-ordered formation of higher order PSD-95 complexes. At the same time, however, such changes free the GK domain from inhibitory effects of the intramolecular SH3 interaction, and thereby facilitate interaction with other proteins, such as Gnb5.

> 3\) The authors tend to overgeneralize/lack precision on some key elements. Their initial article (Rademacher et al., 2013) only showed that PSD-95 and not synaptic MAGUK proteins oligomerized upon PDZ domain ligand binding. Other reports indicate different behavior within the PSD-95 family with respect to oligomerization (Zeng et al., 2018 -- and not 2017). Similarly, the authors often use the term PDZ3 ligand leading the reader to believe that any PDZ3 ligand will have the same effect. However they have only used two ligands -CRIPT and Neuroligin- and again other reports indicate a difference between CRIPT and another PDZ3 ligand, SynGAP, on their effect on the PSG module (Zeng et al., 2018).

It is true that this study is focused on PSD-95 and not on synaptic MAGUK proteins in general, and we have made an effort to be more specific with our word choice throughout the revised manuscript. For example, we have now specified that we mean the "MAGUK protein PSD-95" rather than referring simply to "MAGUK protein" at relevant points within the text (see paragraph one of the Introduction).

In order to focus on the effects of ligand binding to PDZ3 rather than general ligand binding to PDZ domains in PSD-95, we have selected ligands that are historically known for interacting predominantly with PDZ3, which is the case for both NLGN1 and CRIPT (Irie et al., 1997; Niethammer et al., 1998). Our cell-based experiments described in Figure 1 build on our previous work on how ligand binding to PDZ domains influences PSD-95 multimerisation (Rademacher et al., 2013). For the cell-based experiments in Figure 1 of this manuscript, we elected to use full-length proteins that have a solid history as postsynaptic interaction partners and therefore selected NLGN1 as our PDZ3 ligand.

In subsequent experiments we took advantage of the CRIPT C-terminus to produce a generic binder of PDZ3, for the purpose of investigating in general how ligand binding at PDZ3 of PSD-95 influences the scaffolding behaviour of this molecule and specifically how it influences the behavior of PSD-95 in intra-and inter-molecular protein-protein interactions. We used the CRIPT C-terminus for this purpose in part because it has a long history as a PSD-95 PDZ3-binding protein, and also because it is the most efficient and specific PDZ3-binding ligand in our hands. In order to make things clearer and prevent misunderstandings, we have now consistently specified throughout the text which PDZ3 ligand we have used for which experiments. We have also added an introductory sentence in the results (Results section entitled "Ligand binding to PSD-95 PDZ3 facilitates an "open" SH3-GK state that frees both domains for binding in trans") explaining our choice of the CRIPT C-terminus for pursuing the main questions addressed in this study.

> Of note, the molecular mechanism by which SynGAP interaction leads to PSD-95 oligomerization is clearly presented in that same study, despite what is written in the discussion (referring to an older citation).

In response to this point, we have modified our discussion to include more detail on the results of Zeng et al., 2017 (see paragraph two of the Discussion and also the final paragraph of the Discussion).

> 4\) Along these lines, considering that CRIPT and SynGAP led to different results for PSD-95 oligomerization in Zeng et al., 2018, it would be interesting to clarify how the present results compare to the one obtained with the SynGAP PDZ3 ligand. Another point is that while CRIPT is, to my knowledge, a monomer, full-length Neuroligin is a dimer which complicates the interpretation of the results of the first section and raises the question if the same oligomerization mechanism is observed.

We acknowledge that NLGN1 is capable of forming dimers. Our cell-based splitEYFP assay includes the scaffold-deficient L460P control that hinders complex formation despite the possible presence of NLGN1 dimers (see Figure 1D), which supports the idea that the observed EYFP refolding reflects complex formation that depends on the functionally intact SH3-GK domain rather than on the dimerisation properties of NLGN1 molecules. This initial result is in line with our previous work with the CRIPT PDZ ligand (Rademacher et al., 2013), but the effects of SynGAP have not been tested yet. A rigorous comparison of the similarities and differences between NLGN, CRIPT, and SynGAP with regard to how they influence the scaffolding properties of PSD-95 in our assay is of interest and certainly worth pursuing further experimentally. In this context, further investigations into how different PDZ binders influence PSD-95 interactions and thereby steer the formation of specific complexes (both temporally and spatially) is also relevant, and we have highlighted these interesting avenues for further study in our modified discussion. We feel, however, that these questions extend beyond the aims and scope of this study, given that our focus here is on ligand-mediated conformational alterations to the PSD-95 molecule and resulting physical consequences, rather than on the complex biology of the precursor steps.

> 5\) The claim that Gnb5 and GKAP occupy different subdomains is not supported by totally convincing data. The results clearly show a different mode of interaction but do not exclude the fact that it could be the same subdomain. Simultaneous co-precipitation of the two GK partners, if successful, could support such a claim.

Indeed our data do not enable us to conclude which precise surface of the GK domain is involved in the interaction with Gnb5. This is a relevant point and one that we are investigating. We are currently using a targeted approach in which we mutate selected amino acids throughout the GK domain sequence with the aim of interfering with the Gnb5-GK interaction. Based on existing structural models of the GK domain, we have already tested several single amino acid changes; so far, however, we have not observed dramatic effects on Gnb5 binding (as we observe for the R568A mutation with regard to GKAP binding). An additional aspect of this approach, which we will also pursue in the future, involves crystallisation of the GK domain in complex with Gnb5 in order to precisely identify the best residues for targeted mutation.

Simultaneous coprecipitation is another method that can be used to explore this idea. We know that after pulldown of the isolated GK domain we can coprecipitate GKAP and Gnb5. Following triple transfection (in which both GKAP and Gnb5 are simultaneously expressed) and pulldown of the GK domain, we expect to find both of these proteins in the coprecipitate, even if they bind to the same surface of GK, as we will pull down sufficient GK molecules for participation in both interactions. In order to prove that the proteins do not compete for the same binding surface, our approach involved a triple transfection of the three constructs and pulldown of Gnb5, followed by analysis of GKAP (or vice versa), i.e. we attempted to isolate the three proteins in a single complex. Although we were indeed able to coprecipitate the GK domain using this strategy, we did not observe formation of a complex in which all proteins could be detected. There are several possible explanations for this. Of course it is possible that Gnb5 and GKAP indeed occupy partially overlapping regions of the GK domain. It is also possible that we simply do not have adequate coprecipitation of the GK domain to enable enrichment of the third binding partner. Pulldown experiments in which we immunoprecipitate the GK domain directly consistently yield substantial amounts of GK in the precipitate; with our triple transfection approach, however, GK levels in the precipitate are low. It is also possible that the presence of a large protein bound to GK at one surface simply precludes binding at a neighbouring site due to stearic hindrance. Indeed, given what is known about these two proteins, we would not necessarily expect them to bind simultaneously to the same PSD-95 molecule in neurons. While GKAP binds to PSD-95 molecules at the core of the PSD, it is plausible that Gnb5 instead links less central PSD-95 molecules with membrane proteins at the periphery of the PSD. These are questions that we intend to pursue in future studies; we have expanded on these ideas in the revised discussion.

Importantly, in response to this issue, we have modified the text slightly to avoid overstatements in the revised manuscript. Specifically, we have changed the title of the final Results subsection from "PSD-95 interactors occupy different GK subdomains" to "GK-domain interactions are differentially regulated". We have made the same adjustment to the title of Figure 5.

> 6\) The method that the authors use to isolate \"synaptic proteins\" using a reagent sold by Thermo-Fisher has not been verified in any peer-reviewed publication. A search of the online references listed on the Thermo-Fisher website does not contain any method that can reliably enrich for synaptic proteins without the use of a density gradient. The inadequacy of the method is revealed, for example, by the high level of ribosomal proteins listed in the author\'s Figure 2---source data 1. In subsection "The SH3-GK assembly state influences PSD-95 interactions with synaptic proteins", the authors cite the overlap between their list of proteins and that of Wilkinson et al., 2017. However, Wilkinson et al. did not use a method that enriches for synaptic proteins. They simply extracted a crude membrane pellet from a brain homogenate with detergent to obtain detergent insoluble proteins. The extracted pellet would contain microsomes and mitochondria, in addition to synaptosomes. This fraction is not a postsynaptic density fraction because it skips the step of isolating synaptosomes from the brain homogenate. For the continued integrity of the literature, the authors should eliminate statements that indicate that they are working with \"synaptic proteins\" or \"postsynaptic density\" proteins. They should eliminate the reference to the Wilkinson paper completely as it does not support their statement that they are working with synaptic proteins. The authors have wisely chosen to work with a protein that has been shown to be located in the excitatory postsynaptic compartment, and to play an important role there (regulation of GIRK channels by GABAB receptors). They have verified the synaptic location of the particular protein they have studied. Nonetheless, all claims to have started with anything other than a detergent insoluble extract of a crude brain membrane fraction should be removed.

Point well taken. We acknowledge that the strategy we have used to generate lysates that contain synaptic proteins is not by any means one that yields pure synaptosomes, and the description of the method we used for protein isolation in our original manuscript was not adequate. Given the reagents and methods we have used, and in light of the reviewers' concerns, we have reconsidered how we describe our work and how we compare it to data generated by other groups. Importantly, we now describe in more detail in the Materials and methods section the steps involved in generating our protein lysates. We acknowledge that our protocol yields a membrane fraction from brain that is enriched for synaptosomal proteins, but also contains mitochondrial proteins and other non-synaptic membrane contaminants. There is some flexibility across the literature with regard to how people refer to such a preparation. We have opted to maintain our use of the term "crude synaptosome preparation", and we have corrected the text in the two places where we made the error of referring to "synaptic protein lysates" or "synaptosomes" in the original submission. We additionally deleted "synaptic proteins" from the title of the third subsection of the Results and adjusted the corresponding text of Figure 2A to "crude synaptosome preparation".

We also acknowledge that the classical cell fractionation method, involving ultracentrifugation and use of a sucrose gradient, is the reliable method for producing a pure synaptosome fraction and subsequent PSD fraction (Carlin et al., 1980). For this reason, we have decided to remove the comparison of our identified proteins with the list generated by Wilkinson et al. Instead we have now compared our list to the list of PSD proteins generated by Baye et al., (Bayes et al., 2012), who used a classical approach for isolating PSD proteins based on the methods described by P. Siekevitz and colleagues (see the third subsection of the Results entitled "The SH3-GK assembly state influences PSD-95 interactions").

> 7\) There is not enough information in the Materials and methods section about how flow cytometry was performed and no actual plots of data distribution are shown as would be customary for such analysis, including the presumed existence of various populations of cells. Did the authors stain for cell viability (like propidium iodide) to exclude defective cells?

We have now included exemplary FACS plots for every construct combination we have analysed in the manuscript (see results in Figure 1C and Figure 1D) as a Supplementary file (Figure 1---figure supplement 1 FACS). During establishment of the FACS assay, we regularly included a propidium iodide control to identify cells with damaged membranes. Given that we could efficiently exclude these π positive objects in further analyses by taking advantage of gating strategies to define living cells in the forward vs. side scatter plot, we no longer include the propidium iodide control regularly in our experimental plan. Indeed the description of our cell sorting assay was brief in our original submission and much of this information was lacking. In addition to the exemplary FACS plots now attached to Figure 1 (Figure 1---figure supplement 1), our revised manuscript also includes a thorough description of the FACS procedure that includes the details of our gating strategy (see revised Materials and methods).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> In this first revision, the authors have responded adequately to some, but not all of the major comments on the original manuscript. They have included quantitation and statistical analysis of all of their experiments as appropriate. They have included a new control (SynCAM1) in their transfections to strengthen the conclusion that the interaction of the two halves of EYFP fused to neuroligin and transfected into 293 cells requires interaction of neuroligin with a PDZ domain of PSD-95.
>
> However, the authors have not responded adequately to the criticism that they have over-generalized and lack precision in their writing. There are two aspects of this problem.
>
> 1\) The authors conflate the finding that the CRIPT 10-mer \"opens-up\" the GK domain exposing a new domain that binds to Gnb5, with the generalization that the CRIPT 10-mer promotes multimerization of PSD-95 (which they believe also leads to dimerization of tagged neuroligin). The implication is that the multimerization of PSD-95 arises from the \"opening up\" of the GK and SH3 domains so that they can interact in trans with other proteins. This generalization conflicts with the finding reported by Zeng et al. in Journal of Molecular Biology (2018) that binding of a peptide containing the final 17 residues of CRIPT (CRIPT 17-mer) to PDZ3 does NOT lead to multimerization of PSD-95; whereas binding of a peptide containing the final 15 residues of synGAP DOES result in multimerization of PSD-95.
>
> Communication about this issue may have been obfuscated by the fact that the authors have mis-stated the year of this Zeng et al. publication as 2017. The authors need to fix the citation of the J. Mol. Bio. paper by Zeng et al. by changing the year to 2018. Note that a later Cell paper published by Zeng et al. in 2018 on a similar topic is actually not relevant to the present study and should not be cited.
>
> \[...\]
>
> To resolve the apparent conflict between their data and that of Zeng et al., the authors should compare the effect of a CRIPT 17-mer in their assays to the effect of the CRIPT 10-mer and test directly for dimerization of the PSD-95 construct after binding of the peptides by size-exclusion chromatography or another method that would unambiguously detect dimerization of PSD-95.

Our response to point 1 is multifaceted and includes, for clarification, a summary of our current approach and how it differs from our work in previous studies.

A minor aspect of our study focusses on the idea that binding of ligands to the third PDZ domain of PSD-95 can influence PSD-95 multimerisation. This question was the focus of our previously published work (Rademacher et al., 2013), in which we took advantage of the CRIPT PDZ ligand and demonstrated that binding of monomeric CRIPT-derived C-termini to PDZ3 promoted interactions between PSD-95 molecules. In this previous study, we also demonstrated that this multimer formation brought CRIPT-derived PDZ ligand C-termini into close proximity of each other (as shown by refolding of EYFP when CRIPT ligand sequences fused to non-fluorescing EYFP halves were expressed together with PSD-95 or PSD-95 fragments). In the current study, we have used a new BiFC strategy that integrates full-length PSD-95 molecules fused to non-fluorescent EYFP halves -- and we have shown that expression of NLGN also promotes PSD-95 multimolecular complex formation. Importantly, we show in this study that this process relies on both successful ligand binding to the PDZ domains AND the integrity of the SH3-GK domain module (see Figure 1). However, the mechanistic details of PSD-95 multimerisation, which in our hands can be induced by both NLGN and CRIPT, is not the focus of our current study.

We observe, in both previous and current studies, that tagged CRIPT-derived C-termini induce changes in the behaviour of the PSD-95 PSG module, and here we have successfully taken advantage of this phenomenon to isolate new GK binders that are regulated by ligand-PDZ domain interactions. It is this idea that is the central theme of this study. We focus specifically on the regulated interaction between PSD-95 and Gnb5, a novel GK domain interactor whose affinity for PSD-95 is regulated by binding of CRIPT-derived ligands to PSD-95 PDZ3. Our CoIP data are in line with the model that the PSD-95 SH3-GK domain module indeed "opens up" in response to binding of CRIPT-derived ligands to PDZ3, and that this conformational change is what enables binding to Gnb5. While it seems plausible that similar mechanisms underly PSD-95 multimer formation, we have not investigated this question directly in this study and therefore have made efforts to remove any misleading generalisations that suggest something different. For example, we have removed the following sentence in the Discussion: "Here, we show that PSD-95 oligomerisation can be induced by binding of monomeric PDZ3 ligands, which then leads to conformational changes within the adjacent C-terminal SH3-GK domain structure."

Instead we refer directly to our previous work: "In previous work, we showed that binding of CRIPT-derived ligands to PDZ3 of PSD-95 promoted formation of PSD-95 multimers." Later we summarise our current work: "Here we identify synaptic interactors whose association with PSD-95 is influenced by the conformational state of the PSD-95 C-terminus."

We have also removed the following general sentence later on in the Discussion: "Via this mechanism, ligand-PDZ3 domain interactions facilitate formation of both homotypic and heterotypic complexes guided by the PSD-95 C-terminal PSG module."

Finally, we recognize that in in vitro biochemical assays, tagged protein fragments (as we use here) or peptides (as used in Zeng et al., 2018) often replace full-length proteins for simplicity in experimental design and that these strategies are inevitably limited in terms of applicability to the in vivo situation. In order to confirm the in vivo validity of our experiments, and understand why CRIPT peptides do not induce multimerisation of PSD-95 PSG molecules in other labs (Zeng et al. 2018), multiple strategies, that ideally make use of full-length proteins, are required. Certainly, a comparison of how wild-type CRIPT, NLGN, and SynGAP influence PSD-95 complex formation and specifically the interaction between PSD-95 and novel binding partner Gnb5 is of interest, especially in light of the apparent discrepancy between our results and those of Zeng et al. 2018 with regard to how CRIPT-derived fragments influence PSD-95 multimer formation. However, this should be pursued in future studies using wild-type and/or endogenous proteins, rather than using peptides (as done by Zeng et al. 2018) or proteins fragments (as we have done here). These experiments are planned, but they extend beyond the scope of this study.

Finally, we appreciate your clarification regarding the Zeng et al., 2018 references and we have now removed the Zeng et al., 2018 (Cell) references, which is less directly related our study.

> 2\) The authors continue to inappropriately generalize their results to all PDZ3 binding ligands. For example:
>
> In the Abstract, \"Here we show that binding of monomeric PDZ3 ligands to the third PDZ domain of PSD-95 induces functional changes in the intramolecular SH3-GK domain assembly that influence subsequent homotypic and heterotypic complex formation.\"
>
> \"...this interaction is triggered by PDZ3 ligands binding to the third PDZ domain of PSD-95,...\"
>
> Introduction section: We have previously shown that synaptic MAGUK proteins oligomerise upon binding of monomeric PDZ3 ligands (ligands that specifically bind to the third PDZ domain) (Rademacher et al., 2013) and speculated that ligand -- PDZ3 domain binding induces conformational changes in the C-terminal domains that lead to complex formation.\"
>
> This generalization to all PDZ3 ligands is repeated in several places in the manuscript. The authors should replace the term PDZ3 ligand with the name of the specific ligand that the authors use in each experiment.

We acknowledge that we have not been adequately specific in the description of our results with regard to the PDZ ligands used in our experiments, and we have made relevant changes throughout the manuscript in order to indicate very clearly how each experiment was done and which ligand was used. For examples, see:

Figure 1 E legend

Figure 4 title

Figure 4 A and B legends

Figure 5 B and C legends

Figure 6 legend

We have also adjusted statements in which our wording implied that we were referring to PDZ3 ligands in general. For example, in the Abstract, Introduction, Results subsection "Neuroligin-1 binding to PSD-95 PDZ3 domains facilitates oligomerisation guided by the PSG module" and "Binding of a CRIPT-derived PDZ ligand to PSD-95 PDZ3 facilitates an "open" SH3-GK state that frees both domains for binding in trans", and in numerous other points in the text we have now specified "CRIPT-derived PDZ3 ligands' instead of using the more general 'PDZ3 ligands".
